Abstract
An antibody against the lecithin:cholesterol acyltransferase (LCAT) enzyme, which negates cholesterol esterification in plasma, causing severe high-density lipoprotein deficiency (HD), was identified in a woman with a large-cell non-Hodgkin lymphoma. Successful treatment of the lymphoma resulted in clearance of the antibody and complete correction of the defective cholesterol esterification and HD. To our knowledge, an acquired LCAT deficiency leading to severe HD has not been reported previously in association with a malignant disease, and this patient represents the first such documented case.
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Apolipoprotein A-I / blood
-
Apolipoprotein A-II / blood
-
Autoantibodies / blood*
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / therapeutic use
-
Female
-
Humans
-
Immunoglobulin G / immunology
-
Lipoproteins, HDL / blood
-
Lipoproteins, HDL / deficiency*
-
Lipoproteins, LDL / blood
-
Lymphoma, Non-Hodgkin / diagnosis*
-
Lymphoma, Non-Hodgkin / drug therapy
-
Phosphatidylcholine-Sterol O-Acyltransferase / blood
-
Phosphatidylcholine-Sterol O-Acyltransferase / immunology*
-
Prednisone / therapeutic use
-
Rituximab
-
Severity of Illness Index
-
Triglycerides / blood
-
Vincristine / therapeutic use
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Apolipoprotein A-I
-
Apolipoprotein A-II
-
Autoantibodies
-
Immunoglobulin G
-
Lipoproteins, HDL
-
Lipoproteins, LDL
-
Triglycerides
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Phosphatidylcholine-Sterol O-Acyltransferase
-
Prednisone